Dr. Mary Harner
Bristol-Myers Squibb, New Jersey
“Delineation of Screening Hits by NMR Spectroscopy:
While early-phase hits originate from disparate screening approaches, assay formats and libraries, they share one commonality: the need for direct (i.e. biophysical) on-target binding confirmation. As a biophysical tool, NMR spectroscopy is uniquely situated to provide quality control, direct binding, and mechanistic binding assessments on small molecule hits, in addition to its well-documented application as a fragment screening approach. Case studies will be presented that champion NMR’s ability to detect direct binding of hits when all else fails, isolate hits of preferred mechanism, protect against poor assay reference compound selection, and inform HTS assay design. Vignettes will highlight standard ligand- and protein-observed NMR techniques (e.g. STD, HSQC) along with those of emergent usage, such as 19F observation.
6:00 pm Dinner
7:00 pm Seminar
$15 employed / $5 students, postdoc, retired, unemployed. No charge for seminar only.
Where: CABM (Center for Advanced Biotechnology and Medicine)
Rutgers, 679 Hoes Lane West
Piscataway, NJ 08854
Parking: Parking will be available in the front of CABM (see map link given above under Directions)